Samsung Biologics will manufacture biologics on behalf of a European pharma

Published: 2017-09-08 10:16:13

Updated: 2017-09-08 10:16:13

Samsung Biologics will manufacture biologics on behalf of a foreign pharmaceutical company.

Samsung Biologics announced on the 6th that the foreign company was a pharmaceutical company headquartered in Europe and it signed a letter of intent for contract manufacturing of biologics worth of KRW 10.5 billion(account for 2.57% of total sales in the latest fiscal year) on the 6th of September.

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.